What Is New in Fungal Pharmacotherapeutics?

April 2014 | Volume 13 | Issue 4 | Original Article | 389 | Copyright © April 2014


Ethan T. Routt MD,a Shelbi C. Jim On MD,a Joshua A. Zeichner MD,a and Leon H. Kircik MDb,c,d

aIcahn School of Medicine at Mount Sinai, New York, NY bDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN cPhysicians Skin Care, PLLC, Louisville, KY dDepartment of Dermatology, Mount Sinai School of Medicine, New York, NY

The remaining authors have not disclosed any relevant conflicts.

REFERENCES

  1. James WD, Berger TG, Elston DM. Andrew’s Disease of the Skin Clinical Dermatology. 11th Edition, Philadelphia, PA, Elsevier/Saunders, 2011.
  2. Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013; 32(suppl):S2-S4.
  3. Ghannoum MD, Hajjeh RA, Scher R. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641-648.
  4. Pariser D. The rationale for renewed attention to onychomycosis. Semin Cutan Med Surg. 2013; 32(suppl): S1.
  5. Elewski B, Pariser D, Rich P, Scher RK. Current and Emerging Options in the Treatment of Onychomycosis. Semin Cutan Med Surg. 2013;32:S9-12.
  6. ONMEL (FDA package insert). Greensboro, NC:Merz Pharmaceuticals, LLC; 2012. Accessed 11/10/13 at http://onmel.com/wp-content/uploads/ONMEL-full-prescribing-information.pdf.
  7. Elewski BE, Rich P, Pollak R et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013 Apr; 68(4):600-608.
  8. Tosti A. Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis. Cutis. 2013 Oct;92(4):203-8.
  9. Tatsumi Y, Nagashima M, Shibanushi T et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May; 57(5):2405-9.
  10. Elewski BE. Efinaconazole 10% solution: a new topical antifungal therapy for onychomycosis. Expert Rev Dermatol. 2013; 8(4):347-356.
  11. Jo Siu WJ, Tatsumi Y, Senda H et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013 Apr; 57(4):1610-6.
  12. Patel T, Dhillon S. Efinaconazole: First Global Approval. Drugs. 2013; 73:1977-1983.
  13. Fernando LR, Mao W, Yaremchuk A et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007; 316:1759-1761.
  14. Zane LT, Pollak RA. Safety and Efficacy of Tavaborone (Formerly AN 2690), a Novel Boron-based Molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. 2012 Aug.
  15. Baker SJ , Hui X, Sanders V, et al. Nail Penetration of AN2690: Efficacy Coefficient and Effect of Formulation. 2006. Available at: http://www.anacor.com/pdf/ESDR_P91.pdf. Accessed 11/9/13.
  16. Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin. Pharmacother. 2012;13(8): 1131-1142.
  17. Hui X, Baker SJ, Wester RC, et al. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci. 2007;96(10):2622-31.
  18. Al Hasan M, Fitzgerald SM, Saoudian M, et al. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy. 2004, 2:5.
  19. Havlickova B, Czaika VA, Freidrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008; 51(Suppl. 4):2-15.
  20. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines for care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guiedelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996; 34(2):282-286.
  21. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(Suppl 1):1-10.
  22. Kosinski M, Joseph WS, Markinson B. Advances in the Treatment of Tinea Pedis. Podiatry Management. 2007 June/July; 227-242.
  23. Choi TS, Solomon B, Nowakowski M, et al. Effect of naftifine on neutrophil adhesion. Skin Pharmacol. 1996; 9(3):190-6.
  24. Ghannoum M, Isham N, Verma A, Plaum S, Fleischer A, Hardas B. In vitro Antifungal Activity of Naftifine Hydrochloride against Dermatophytes. Antimicrob Agents Chemother. 2013; 57(9):4369-4372.
  25. Monk JP, Brogden RN. Naftifine: A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991; 42(4):659-672.
  26. Stein Gold LF, Parish LC, Vlahovic T, et al. Efficacy and Safety of Naftifine HCL Gel 2% in the Treatment of Interdigital and Moccasin Type Tinea Pedis: Pooled Results from Two Multicenter, Randomized, Double-Blind, Vehicle-Controlled Trials. J Drugs Dermatol. 2013; 12(8):911-918.
  27. NAFTIN Gel, 2% [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; June 2013. 2. Data on file, Merz Pharmaceuticals, LLC. http://naftin.com/wp-content/uploads/NAFTIN-Gel-2-Pl.pdf. Accessed 11/9/13
  28. Del Rosso JQ, Kircik LH. Optimizing Topical Antifungal Therapy for Superficial Cutaneous Fungal Infections: Focus on Topical Naftifine for Cutaneous Dermatophytosis. J Drugs Dermatol. 2013; 12(11):S165-171.
  29. Plaum S, Verma A, Fleischer A, Olayinka B, Hardas B: Detection and Relevance of Naftifine Hydrocloride in the Stratum Corneum Up to Four Weeks Following the Last Application of Naftifine Cream and Gel, 2%. J Drugs Dermatol. 2013; 12(9);1004-1008.
  30. Koga H. Nanjoh Y, Makimura K et al. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009; 47(6):640-7.
  31. Jarratt M, Jones T, Kempers S, et al. Luliconazole for the treatment of interdigital tinea pedis: a double-blind, vehicle controlled study. Cutis. 2013; 91:203-210.
  32. Jones T, Tavakkol A. Safety and Tolerability of Luliconazole Solution, 10% in Patients with Moderate to Severe Distal Sunungual Onychomycosis. Antimicrob. Agents Chemother. 2013; 57(6):2684-9.
  33. Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis – comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomized double-blind study. Mycoses. 2007; 50:35-40.
  34. Little LW. Valeant Pharmaceuticals Announces U.S. Approval of Luzu Cream, 1%. 2013 Nov. Available at: http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-US-Approval-Of-Luzu-Cream-1/default.aspx. Accessed 11/19/13.

AUTHOR CORRESPONDENCE

Leon H. Kircik MDwedoderm@yahoo.com
Close Menu